請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37305
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 倪衍玄(Yen-Hsuan Ni),張美惠(Mei-Hwei Chang) | |
dc.contributor.author | Wei-Ju Su | en |
dc.contributor.author | 蘇韋如 | zh_TW |
dc.date.accessioned | 2021-06-13T15:23:55Z | - |
dc.date.available | 2009-08-14 | |
dc.date.copyright | 2008-08-14 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-22 | |
dc.identifier.citation | 1.Douglas DD, Rakela J, Mamish D, Wright TL, Krom RAF, Wiesner RH. Transmission of hepatitis B virus (HBV) infection from orthotopic donor livers. Hepatology 1992: 16: 49A.
2.Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBcIgM(-) organ donors. Transplantation 1995:59:230-234. 3.Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002;8:S82–S87. 4.Sung JL. Hepatitis B virus infection and its sequelae in Taiwan. Gastroenterol Jpn 1984: 19:363-366. 5.Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF, Jardí R, Margarit C, Pumarola T, Esteban R, Guardia J. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transp 2002;8:892–900. 6.Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, Kiuchi T, Miyake Y, Tanaka K, Chiba T. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998;65:494–499. 7.Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, Kelley M, Bozorgzadeh A. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine. Transplant Proc 2005: 37: 3187-3189. 8.Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68:1058–1061. 9.Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, Nishida S, Madariaga J, Kato T, Ruiz P, Schiff E, Tzakis AG. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003;75:1179–1186. 10.Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002;137:572–575. 11.Abdelmalek MF, Pasha TM, Zein NN, Persing DH, Wiesner RH, Douglas DD. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003: 9: 1253-1257. 12.Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001: 13: 359-361. 13.Crespo J, Fabrega E, Casafont F, Rivero M, Heras G, De La Pena J, De La Cruz F, Pons-Romero F. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999: 5: 175-183. 14.Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, David MF, Arulnaden JL, Bismuth A, Reynes M, Bismuth H. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997;26:517–526. 15.Segovia R, Sanchez-Fueyo A, Rimola A, Grande L, Bruguera M, Costa J, Soguero C, Uriz J. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 2001: 7: 106-112. 16.Toniutto P, Fumo E, Caldato M, Apollonio L, Perin A, Pirisi M. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2004: 77: 472-473. 17.Lo CM, Fung TKJ, Lau KKG, Liu CL, Cheung ST, Lai CL, Fan ST, Wong J. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003:37:36-43. 18.Ni YH, Chang MH, Chen PJ, Tsai KS, Hsu HY, Chen HL, Tsuei DJ, Chen DS. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007;132;2340-2345. 19.Chang SH, Suh KS, Yi NJ, Choi SH, Lee HJ, Seo JK, Lee KU. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatololgy 2003;37:1329–1334. 20.Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, Jawan B, Chiu KW, Chen CL. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core positive donors. Clin Transplant 2002;16:405–409. 21.Lin CC, Chen CL, Concejero A, Wang CC, Wang SH, Liu YW, Yang CH, Yong CC, Lin TS, Jawan B, Cheng YF, Eng HL. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant 2007;7:195–200. 22.Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transmission to adult and pediatric recipients in Taiwan. J Hepatol 2006;44:39–46. 23.Lee KW, Lee DS, Lee HH, Kim SJ, Joh JW, Seo JM, Choe YH, Lee SK. Prevention of de novo hepatitis B infection from HBcAb-positive donors in living donor liver transplantation. Transpl Proc 2004;36:2311–2312. 24.Rokuhara A, Tanaka E, Yagi S, Mizokami M, Hashikura Y, Kawasaki S, Kiyosawa K. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome. J Med Virol 2000; 62: 471-478. 25.Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, Marchiaro G, Salizzoni M, Rizzetto M. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl 2004 Mar;10(3):356-362. 26.Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M; Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005 J;25: 472-489. 27.Sugauchi F, Orito E, Ohno T, Kato H, Suzuki T, Hashimoto T, Manabe T, Ueda R, Mizokami M. Liver transplantation-associated de novo hepatitis B virus infection: application of molecular evolutionary analysis. Intervirology 2002;45 : 6-10. 28.Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, Chiba T. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006; 6: 2680-2685. 29.Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, Yeh SH, Jeng YM, Tsai KS, Chen DS. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004;127:1733-1738. 30.Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, Huang WL, Lu SF, Jih J, Chen DS, Chen PJ. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659-666. 31.Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, Zetterman RK, Pruett TL, Ishitani MB, Hoofnagle JH. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997;113:1668–1674. 32.Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and University of Tokyo experience. Dig Dis Sci 2007;52:2472–2477. 33.Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J. De novo hepatitis B after liver transplantation from hepatitis B core antibody–positive donors in an area with high prevalence of anti-HBc positivity in the donor Population. Liver Transpl 2001;7:51–58. 34.Ni YH, Chang MH. The ways paved for prophylaxis against de novo hepatitis B virus infection after liver transplantation- still many stones left unturned. Pediatr Transplant 2006;10:405–407. 35.Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, Ascher NL, Wright TL. 'Occult' hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343:142–146. 36.Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479–486. 37.Chalasani N, Smallwood G, Halcomb J, Fried MW, Boyer TD. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998;4:128–132. 38.Carey W, Pimentel R, Westveer MK, Vogt D, Broughan T. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am J Gastroenterol 1990;85:1590–1592. 39.Loinaz C, de Juanes JR, Gonzalez EM, López A, Lumbreras C, Gómez R, Gonzalez-Pinto I, Jiménez C, Garcia I, Fuertes A. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterol 1997;44:235–238. 40.Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, Lumeng L, Chalasani N. Vaccination against hepatitis B in patients with chronic liver diseases awaiting liver transplantation. Am J Med Sci 1999;318:304–307. 41.Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver diseases. Liver Transpl 2001;7:314–320. 42.Bárcena Marugán R, García-Hoz F, Vázquez Romero M, Nash R, Mateos M, González Alonso R, García González M, García Plaza A. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 2002;97:2398–2401. 43.Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336:325–329. 44.Echevarria JM, Avellon A. Hepatitis B virus genetic diversity. J Med Virol 2006;78 Suppl 1:S36–S42. 45.Hsu HY, Chang MH, Ni YH and Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationalwide vaccination programme in Taiwan. Gut 2004;53:1499-1503. 46.Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, Chen DS. Two decades of universal hepatitis B vaccination in Taiwan: Impact and implication for future strategies. Gastroenterology 2007;132:1287-1293. 47.Ly TD, Servant-Delmas A, Bagot S, Gonzalo S, Férey MP, Ebel A, Dussaix E, Laperche S, Roque-Afonso AM. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 2006;44:2321-2326. 48.Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, Ascher NL, Wright TL. 'Occult' hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343:142–146. 49.Toniutto Pierluigi, Fumo Elisabetta, Caldato, Maja, Apollonio Luca, Perin Antonella, Pirisi Mario. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2003;77:472-473 50.Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037-1044. 51.Fortuin M, Karthigesu V, Allison L, Howard C, Hoare S, Mendy M, Whittle HC. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994;169:1374-1376. 52.Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997;26:786-791. 53.Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999;30:1312-1317. 54.Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, Waters J. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996;24:489-493. 55.Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213-222. 56.Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, Neuhaus P, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-263. 57.Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999;52:25-137. 58.Lee KM, Kim YS, Ko YY, Yoo BM, Lee KJ, Kim JH, Hahm KB, Cho SW. Emergence of vaccine-induced escape mutant of hepatitis B virus with multiple surface gene mutations in a Korean child. J Korean Med Sci 2001;16:359-362. 59.McNair ANB, Viaggi P, Smith HM, Tibbs CJ, Naoumov NV, Williams R. Hepatitis B envelope protein mutants. Lancet 1995;346:318-319. 60.Hawkins AE, Gilson RJ, Gilbert N, Wreghitt TG, Gray JJ, Ahlers-de Boer I, Tedder RS, Alexander GJ. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996;24:8-14. 61.Wallace LA, Carman WF. Surface gene variation of HBV: scientific and medical relevance. Viral Hepatol Rev 1997;3:5-16. 62.Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997;4:11-20. 63.Tatyana Kalinina, Alicja Iwanski, Hans Will, and Martina Sterneck. Deficiency in Virion Secretion and Decreased Stability of the Hepatitis B Virus Immune Escape Mutant G145R. Hepatology 2003;38:1274-1281. 64.Awerkiew S, Däumer M, Reiser M, Wend UC, Pfister H, Kaiser R, Willems WR, Gerlich WH. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007;38:83-86. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37305 | - |
dc.description.abstract | 非B肝相關肝病接受肝移植後才測得B肝病毒表面抗原陽性,定義為新生B型肝炎病毒感染(de novo HBV infection)的病人。對於罹患新生B型肝炎病毒感染的病人其長期追蹤後的臨床表現,我們所知有限。本研究乃探討非B肝相關肝病兒童換肝後罹患新生B型肝炎感染之發生率、危險因素、及臨床預後。
從1996到2006年間,有71位病童於臺大醫院接受B肝表面抗原陰性之活體肝臟或屍肝移植,這些病童在換肝前都不是B肝帶原者。受贈者在肝移植後會規則地檢驗肝功能、血清中免疫抑制劑藥物的濃度、並持續追蹤換肝後B肝與C肝之血清標記。肝移植前,病童的B肝疫苗接種劑數、B肝血清標記、及B肝表面抗體的效價都被紀錄,同時捐贈者的B肝血清標記亦有記載。罹患新生B型肝炎的病童,其在感染初期所保存之血清,會先以即時定量聚合鏈反應來檢測B肝病毒之病毒量與基因型,並進一步以聚合酶連鎖反應來定出B肝病毒的全部核苷酸序列;另外代表肝功能指標的丙氨酸轉氨酶(ALT)超過兩倍正常值時,會進行肝穿刺的檢查。肝臟組織學檢查的結果若排除排斥反應或其他原因造成的肝功能異常,則開始給予干安能(lamivudine)治療。 共71位研究對象中,有59位存活。分析存活病童,追蹤時間在1.2至10.2年間(中位數4.6年)。36位(61.0 %)接受來自B肝核心抗體陽性且表面抗原陰性的肝臟捐贈,有48位(81.4 %)在換肝前至少接種過3劑之B肝疫苗。換肝後得到新生B型肝炎的有9位,在換肝後的0.6到4.1年(中位數2.3年)間診斷。換肝前僅保存到49位存活者之血清,檢測其B肝表面抗體的效價,得知換肝前表面抗體大於200 mIU/ml,是預防換肝後新生B型肝炎感染之保護因子(p = 0.02)。換肝後罹患新生B型肝炎的病人,C肝抗體都是陰性,有3位換肝前為B肝核心抗體陽性,有8位接受核心抗體陽性且表面抗原陰性的肝臟捐贈。追蹤這9位換肝後新生B型肝炎感染病童的臨床表現,都沒有發生猛爆性肝炎,有5位B肝表面抗原消失,是在偵測到感染後的3到87個月之間發生;另外4位則持續帶原。共8位服用過或正服用干安能,而表面抗原消失的5位都曾接受過抗病毒藥物治療,當中的3位隨後產生B肝表面抗體,也就是55.5 %(5/9)的病人能走向B肝表面抗原消失的臨床表現,33.3 %(3/9)的病人能達到B肝表面抗原消失隨後產生表面抗體(HBsAg seroconversion)。在中位數2.3年的追蹤中,有4位持續B肝帶原,當中有2位病童,同時有B肝表面抗原與表面抗體的血清標記。僅8位成功取得B肝病毒核苷酸序列,分析後發現罹患新生B型肝炎的肝移植病童中,有75 %(6/8)的病童感染到B肝病毒a抗原決定點的突變株(“a” determinant mutants),而沒有感染到a抗原決定點突變株的有2位,後來都從新生B型肝炎中康復(HBsAg seroconversion)。觀察感染換肝後新生B型肝炎初期所測得之病毒量與追蹤後來的臨床表現,發現走向復原(n=3)的病人,感染初期的病毒量介於 104 到 106 copies/ml之間;只有B肝表面抗原消失(n=2)的病人,感染初期的病毒量約108 copies/ml;而持續帶原者(n=4),感染初期的病毒量介於105到109 copies/ml之間。病毒基因型方面,有7位是B型,有2位是C型。 文獻回顧中都曾探討過有幾個因素會與受贈者罹患新生B型肝炎感染有關,包括接受B肝核心抗體陽性的器官捐贈;受贈者B肝表面抗體的保護效價;移植後免疫抑制劑持續性的使用;以及可能性較低的,受贈者本身在移植前就已經是為潛藏性B型肝炎病毒感染者,卻因移植後發生B型肝炎病毒再活化。根據統計分析的結果,我們定出等待肝移植之病童經由B肝疫苗注射後,若擁有換肝前高效價的B肝表面抗體,即大於200 mIU/ml,可以預防新生B型肝炎的發生。雖然B肝表面抗體,在一定比例接受肝移植的病人身上,因為免疫抑制劑使用下,抗體效價可能會迅速地減低甚至偵測不到,但不論換肝後B肝表面抗體效價會隨著時間增加或減低,持續監測病童肝移植後,B肝血清標記及B肝表面抗體效價的變化是需要的。 無法否認的是,接受核心抗體陽性捐贈者的肝臟移植,是罹患新生B型肝炎感染之主要傳染途徑。換肝前是否具有B肝病毒表面抗體的保護效價,是影響新生B型肝炎感染發生的重要因素之ㄧ。在校正捐贈者核心抗體陽性這個變項後,換肝前B肝病毒表面抗體大於200 mIU/ml,對新生B型肝炎感染的發生仍具保護性(P=0.03),也就是說,不論是否接受核心抗體陽性捐贈者的肝臟移植,我們都建議等待肝移植之病童在換肝前仍擁有大於200 mIU/ml的B肝表面抗體效價。 從追蹤9位罹患新生B型肝炎病童的臨床表現中,有2個訊息可以提示我們罹患新生B型肝炎的肝移植病童可以走向好的預後,分別是感染初期偵測不到a抗原決定點的突變株,也就是表面抗原突變株(HBsAg mutants),與感染初期有低濃度的B肝病毒量。罹患新生B型肝炎感染的9位病童,有3位能走向B肝表面抗原消失隨後產生B肝表面抗體,當中的2位有B肝核苷酸序列可供分析,恰巧都無法在a抗原決定點找到胺基酸突變位點;其他6位有的僅走向表面抗原消失或有的持續帶原狀況者,則在a抗原決定點可以找到胺基酸126、127、129、142、143與 145位點上的突變。感染初期,也就是在9位罹患新生B型肝炎在偵測到B肝表面抗原陽性後平均約1.3個月時(範圍0.0~4.3個月間),以即時定量聚合鏈反應的方法,檢測B肝病毒濃度後發現,病毒濃度低於105 copies/ml似乎只在能走向B肝表面抗原消失隨後產生表面抗體的病童中發生。感染初期低濃度的B肝病毒量與宿主達到更好預後的相關性,仍需要更多的研究來證實。 在沒有周全的預防措施下,兒童換肝後新生B型肝炎的發生率為15.3 %。換肝前B肝表面抗體效價超過200 mIU/ml,可能是足夠預防新生B型肝炎發生的保護因子。B肝表面抗原基因的a抗原決定點突變株發生在新生B型肝炎病童的機率可高達75 %,而沒感染到B肝病毒a抗原決定點的突變株,恰巧都發生在新生B型感染後能康復的病童身上。治療方面,一旦診斷為換肝後新生B型肝炎之病童,會先調降血清中免疫抑制劑的濃度,觀察並注意排斥反應發生的可能,並且在肝功能異常時考慮給予干安能抗病毒藥物的治療,治療目標設定在表面抗原消失且隨後表面抗體產生。從我們的經驗中得知,罹患換肝後新生B型肝炎的病童,有超過一半的比例,能成功地走向B肝表面抗原消失的臨床表現。 | zh_TW |
dc.description.abstract | De novo hepatitis B virus (HBV) infection is defined as HBV surface antigen (HBsAg)-negative patients become HBsAg-positive following organ transplantation. The long-term clinical outcome of de novo HBV infection after orthotopic liver transplantation (OLT) is not understood well. We aimed to assess the incidence, risk factors, and clinical outcome and its relating factors of de novo HBV infection in pediatric liver transplant recipients.
From 1996 to 2006, 71 Taiwanese children with non-HBV-related liver diseases underwent OLT at the National Taiwan University Hospital. All surviving recipients were tested regularly for liver function, serum levels of immunosuppressant, HBsAg, titers of antibodies to hepatitis B surface antigen (anti-HBs), antibodies to hepatitis B core antigen (anti-HBc), and antibodies to hepatitis C virus (anti-HCV). HBV vaccination histories and the anti-HBs titers before OLT were recorded. Children waiting for OLT received the primary universal HBV immunization during their infancy. However, there was no prophylaxis for de novo HBV infection before OLT. When patients acquired de novo HBV infection, drug levels of immunosuppressant, alanine aminotransferase (ALT), and HBV serum markers, including HBsAg, anti-HBs, anti-HBc, and hepatitis B e antigen (HBeAg) and its antibody (anti-HBe) were closely monitored. Lamivudine was administrated when ALT > 80 U/L was noticed and rejection was excluded by histology examination. Meanwhile, immunosuppressant consisted of tacrolimus or cyclosporine tapered to a minimal level without the influence of the graft survival. HBV viral load and genotype were checked by real-time PCR when HBsAg was detected. Furthermore, sequencing was performed to detect any special mutants accounting for de novo HBV infection. Fifty-nine patients (33 females and 26 males) were followed-up for a median of 4.6 years (range, 1.2-10.2 yr). Of these, 36 (61.0%) received allografts from anti-HBc-positive and HBsAg-negative donors. De novo HBV infection was found in nine (15.3%) subjects after OLT, eight of whom received allografts from HBsAg-negative and anti-HBc-positive donors. Forty-eight (81.4%) subjects received three or more doses of HBV vaccine before OLT. Pre-OLT anti-HBs titers were available for 49 recipients. In the group of de novo HBV-infected recipients (n=9), one patients had an anti-HBs antibody titer >200 mIU/ml. In the group of recipients who did not have de novo HBV infection (n=40), twenty-two patients had anti-HB antibody titers >200 mIU/ml (P=0.02). No graft loss or fulminant hepatitis occurred and all were anti-HCV-negative. Five de novo HBV infection recipients underwent HBsAg clearance and the other four were still HBsAg-positive after 2.3 years (range 2.3~2.9 years) of follow-up. Eight of the nine de novo hepatitis B patients had or have taken lamivudine and five of them underwent HBsAg seroclearance. Three of the five had HBsAg seroconversion. For the four patients with HBsAg persistence, two patients were double positive for HBsAg and anti-HBs. HBV DNA sequence was available in 8/9 patients. Seventy-five percent (6/8) of de novo HBV infection children were inoculated by surface mutants. No mutations within “a” determinant were noticed in patients recovered from de novo hepatitis B. In the median of 1.3 months (0.0~4.3 months) after diagnosis of de novo HBV infection, HBV viral loads were ranged from 104 to 106 copies/ml, 108 copies/ml, and 105 to 109 copies/ml for patients with HBsAg seroconversion (n=3), HBsAg seroclerance only (n=2), and HBsAg persistence (n=4), respectively. Seven of the nine patients were infected by genotype B and the other two patients were infected by genotype C. By statistical analysis, we defined that high titers of anti-HBs (>200 mIU/ml) before OLT prevent de novo hepatitis B infection in HBsAg-negative recipients through HBV vaccination. Anti-HBs titers may decline rapidly and become undetectable in a significant proportion of patients post-transplantation. Regardless of whether the anti-HBs titers wax and wane, regular monitoring of anti-HBs titers and HBV serum markers after OLT is essential. The major route of de novo HBV infection is through the allografts from anti-HBc-positive donors. The protective titers of anti-HBs in recipients before OLT play an important role in determining the transmission of de novo HBV to recipients. After adjustment of the variable of donors with anti-HBc, the protective titer of >200 mIU/ml anti-HBs remained significant (P=0.03). We speculated that two factors signaling a better outcome for de novo HBV infection could be the absence of HBsAg variants and lower viral loads (<105 copies/ml) in the early phases of infection. No mutations within “a” determinant were found in patients who recovered from de novo hepatitis B. In contrast to those who could not undergo HBsAg seroconversion, mutations within “a” determinant did exist at aa 126, 127, 129, 142, 143, and 145. Levels of HBV DNA seemed to be lower in patients who ran a resolving course. In conclusion, the incidence of de novo HBV infection in pediatric OLT recipients is 15.3% in the absence of adequate prophylaxis. An anti-HBs titer of >200 mIU/ml before OLT may be sufficient to prevent de novo HBV infection in HBsAg-negative recipients. The incidence of “a” determinant mutants in de novo HBV infection OLT recipients was up to 75%. Absence of HBsAg mutants might be a good prognosis factor. With the help of lamivudine, and possible decreasing the dose of calcineurin inhibitors, the outcome of de novo HBV infection might run a successful HBsAg seroclearance clinical course. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:23:55Z (GMT). No. of bitstreams: 1 ntu-97-P95421020-1.pdf: 559871 bytes, checksum: 275ec40487e0fdab53e1739155774e69 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 口試委員會審定書.......................................i
誌謝...................................................ii 中文摘要...............................................iii 英文摘要...............................................vi 目錄...................................................ix 圖目錄.................................................x 表目錄.................................................xi 論文正文 ㄧ、緒論......................................1 1.背景介紹.................................1 2.研究目的.................................3 二、研究材料與方法............................6 1.個案.....................................6 2.試驗項目.................................6 3.實驗方法.................................8 4.統計方法.................................11 三、結果......................................13 四、討論......................................19 五、展望......................................25 六、論文英文簡述(summary).....................27 參考文獻...............................................43 附錄 中英文縮寫對照表..............................52 圖目錄 圖一、萃取血清中的DNA(Extraction of DNA from serum) 的流程.................................................54 圖二、圖示HBV全長序列所用三段引子(fragment 1, 2, 3) 的核苷酸位點...........................................55 圖三、基因置入與基因選殖(transform and cloning)的流程..56 圖四、萃取質體所轉載之DNA(extraction of Plasmid DNA) 的流程.................................................57 圖五、呈現49位保有換肝前血清的肝移植病童,檢測B肝表面 抗體的效價的結果.......................................58 圖六、追蹤罹患換肝後新生B型肝炎的9位病童其臨床表現.....59 圖七、列舉4位罹患換肝後新生B型肝炎病童,記錄其B肝血清 標記、肝功能...........................................60 圖八、罹患新生B型肝炎病童初期血清中B肝病毒濃度(HBV DNA viral load: copies/ml).............................62 表目錄 表一、本實驗中所使用的PCR引子..........................63 表二、分析59位存活之肝移植病童及其相對應之捐贈者的性 別、肝移植時的年紀、與換肝前B肝血清標記等與罹患新生B 型肝炎之相關性.........................................64 表三、有36位肝移植存活病童是接受核心抗體陽性捐贈者之 肝臟移植,分析這些病童與相對應捐贈者的性別、肝移植時 的年紀、與換肝前B肝血清標記等與罹患新生B型肝炎之相關 性.....................................................65 表四、針對49位保有換肝前血清測得B肝表面抗體效價病童, 以邏輯式回歸法分析罹患新生B型肝炎感染之可能危險因素....66 表五、列出編號9新生B型肝炎病童,從換肝前到換肝後B肝 血清標記的變化與她相對應之肝捐贈者.....................67 表六、列出9位罹患換肝後新生B型肝炎病童及相對應之捐贈 者其換肝前B肝血清標記與相關資訊........................68 表七、罹患換肝後新生B型肝炎病童之臨床特徵..............69 表八、新生B型肝炎病童之初期B肝病毒學及血清學特徵和其 預後...................................................70 | |
dc.language.iso | zh-TW | |
dc.title | 非B肝相關疾病兒童換肝後新生B型肝炎病毒感染之預後及相關危險因素 | zh_TW |
dc.title | Outcome and Risk Factors of de novo HBV Infection in Pediatric Liver Transplant Recipients with Non-HBV Related Liver Diseases | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 高嘉宏(Jia-Horng Kao),許宏遠(Hong-Yuan Hsu) | |
dc.subject.keyword | 新生B型肝炎病毒感染,肝臟移植,B肝表面抗體效價,臨床預後,B肝病毒表面抗原突變株,a抗原決定點突變株, | zh_TW |
dc.subject.keyword | de novo HBV infection,Anti-HBs titer,Liver transplantation,Outcome,HBsAg mutans, | en |
dc.relation.page | 70 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-22 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 546.75 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。